FIELD: medicine.
SUBSTANCE: group of inventions relates to a combined drug for the treatment of undesirable cell proliferation, containing a pyruvate kinase M2 (PKM2) activity modulator and an agent providing a highly mobile group polypeptide box 1 (HMGB1) or a derivative thereof. Group of inventions also relates to a kit for treating undesirable cell proliferation, comprising a PKM2 activity modulator and an agent providing HMGB1 or a derivative thereof; oligophosphorylated polypeptide HMGB1 or its derivative for treatment of undesirable cell proliferation, in which at least one of the tyrosine residues corresponding to amino acids Y109, Y144, Y155 and Y162 of the HMGB1 polypeptide is replaced with a non-phosphorylated amino acid.
EFFECT: group of inventions provides treating undesirable cell proliferation.
20 cl, 8 ex, 3 tbl, 8 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| HMGB1 MUTANTS | 2017 |
|
RU2772733C2 |
| TREATMENT OF CANCER, USING ANTIBODY TO SEMAPHORIN 4D IN COMBINATION WITH EPIGENETIC MODULATING AGENT | 2018 |
|
RU2783535C2 |
| CYCLIC C-TERMINAL PEPTIDE OF ACETYLCHOLINESTERASE IN TREATING OR PREVENTING CANCER OR METASTASIS | 2015 |
|
RU2711161C2 |
| HUMAN EZH2 INHIBITORS AND METHODS FOR APPLICATION THEREOF | 2011 |
|
RU2765155C2 |
| HUMAN EZH2 INHIBITORS AND METHODS OF APPLICATION THEREOF | 2011 |
|
RU2618475C2 |
| NOVEL MODULATORS AND METHODS FOR USE THEREOF | 2011 |
|
RU2592672C9 |
| HGF BETA-CHAIN VERSIONS | 2006 |
|
RU2403261C2 |
| COMBINED THERAPY FOR CANCER TREATMENT | 2013 |
|
RU2699546C2 |
| METHOD FOR MAKING RECOMBINANT HETEROCARPINE | 2003 |
|
RU2359033C2 |
| NEW MODULATORS AND METHODS OF THEIR APPLICATION | 2012 |
|
RU2627176C2 |
